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Condensation: Obese and overweight women exhibit higher Nugent scores and an increased 42 
prevalence of bacterial vaginosis than lean women. 43 
Short Title: Obesity and the prevalence of bacterial vaginosis 44 
AJOG at a Glance: 45 
A. Although several risk factors for bacterial vaginosis have been identified, whether46 
obesity/overweight is a risk factor for bacterial vaginosis is not clear. This study was conducted 47 
to determine whether an association between obesity/overweight and prevalence of bacterial 48 
vaginosis exists and to examine the role of race in this context. 49 
B. Key findings of this study are that obese and overweight women have higher Nugent scores50 
and increased prevalence of bacterial vaginosis. We also show that race is an effect modifier of 51 
the relationship between body mass index and prevalence of bacterial vaginosis. 52 
C. This study uncovers an association between obesity/overweight and frequency of bacterial53 
vaginosis, as well as demonstrating that, unlike white women, black women exhibit higher 54 
Nugent scores and increased prevalence of bacterial vaginosis regardless of body mass index. 55 
56 
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 65 
Abstract 66 
BACKGROUND: Bacterial vaginosis is one of the most common vaginal conditions in the U.S. 67 
Recent studies have suggested obese women have an abnormal microbiota reminiscent of BV; 68 
however, few studies have investigated the prevalence of bacterial vaginosis in overweight and 69 
obese populations. Moreover, despite the increased prevalence of obesity and bacterial vaginosis 70 
in black women, it is not known whether racial disparities exist in the relationship between 71 
obesity and bacterial vaginosis. 72 
OBJECTIVE: The objective of this study was to examine the relationship between body mass 73 
index and bacterial vaginosis as determined by Nugent score and to determine the influence of 74 
race in this context. 75 
STUDY DESIGN: We performed a cross-sectional study using patient data and vaginal smears 76 
from 5,918 participants of the Contraceptive CHOICE Project. Gram stained vaginal smears 77 
were scored using the Nugent method and categorized as BV-negative (Nugent score 0-3), BV-78 
intermediate (Nugent score 4-6), or BV-positive (Nugent score 7-10). Body mass index was 79 
determined using Centers for Disease Control and Prevention guidelines and obese individuals 80 
were categorized as Class I, II, or III obese based on NIH and World Health Organization body 81 
mass index parameters. Linear regression was used to model mean differences in Nugent scores 82 
and Poisson regression with robust error variance was used to model prevalence of bacterial 83 
vaginosis. 84 
RESULTS: In our cohort, 50.7% of participants were black, 41.5% were white, and 5.1% were 85 
of Hispanic ethnicity with an average age of 25.3 years old. Overall, 28.1% of participants were 86 
bacterial vaginosis-positive. Bacterial vaginosis was prevalent in 21.3% of lean, 30.4% of 87 
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overweight, and 34.5% of obese women (p<0.001). The distribution of bacterial vaginosis-88 
intermediate individuals was similar across all body mass index categories. Compared to lean 89 
women, Nugent scores were highest among overweight and obese Class I women (adjusted mean 90 
difference; overweight 0.33 [95% CI 0.14, 0.51] and Class I obese 0.51 [95% CI 0.29, 0.72]). 91 
Consistent with this, overweight and obese women had a higher frequency of bacterial vaginosis 92 
compared to lean women, even after adjusting for variables including race. Among white 93 
women, the prevalence of BV was higher for overweight and Class I and Class II/III obese white 94 
women compared to lean white women, a phenomenon not observed among black women, 95 
suggesting an effect modification. 96 
CONCLUSION: Overweight and obese women have higher Nugent scores and a greater 97 
occurrence of bacterial vaginosis compared to lean women. Black women have a greater 98 
prevalence of bacterial vaginosis independent of their body mass index compared to white 99 
women. 100 
KEYWORDS: bacterial vaginosis, obesity, body mass index, Nugent score, race, overweight, 101 
microbiome 102 
  103 
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Introduction 104 
 Bacterial vaginosis (BV) is one of the most common vaginal conditions in the U.S. and is 105 
present in approximately one out of every three women.1 BV is characterized by lower levels of 106 
beneficial Lactobacilli and an overgrowth of fastidious anaerobic bacteria such as Gardnerella 107 
vaginalis, Atopobium vaginae and species of Prevotella and Mobiluncus.2 Women with BV are 108 
at an increased risk for sexually transmitted infections (STIs; e.g., gonorrhea, chlamydia, HIV, 109 
and trichomoniasis), urinary tract infection, pelvic inflammatory disease, and adverse pregnancy 110 
outcomes including preterm birth.3–13  111 
 112 
Nugent scoring is the gold standard for laboratory-based BV diagnosis and uses morphotype 113 
evaluation of Gram-stained slides to quantify the representation of Gram-positive 114 
(Lactobacillus), small Gram-negative or -variable (Gardnerella, Bacteroides), and curved 115 
organisms (such as Mobiluncus) in vaginal fluid smears.14 These measurements are reported as a 116 
score ranging from 0 to 10, with scores 0-3 indicative of a “normal” Lactobacillus-dominant 117 
microbiota and 7-10 indicating a positive BV diagnosis.  Women with a score of 4 to 6 have an 118 
“intermediate” microbiota, and, similar to BV-positive individuals, may be at greater risk for 119 
acquiring STIs compared to women with a “normal” Lactobacillus-dominant microbiota.8,15–17 120 
Although the pathologic significance of BV-intermediate status is still not clear in all situations, 121 
this type of vaginal microbiota is often considered along with BV as an “abnormal 122 
microbiota”.8,18,19 It is known that several factors including menstruation, 20,21 douching,1,22,23 and 123 
high numbers of sexual partners24 are associated with disruptions of the vaginal microbiota. 124 
Many questions still remain about how BV negatively influences women’s reproductive health. 125 
Unfortunately, there is little mechanistic information about how the dysbiotic BV microbiome 126 
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develops or how individual bacteria interact with the host to produce disease.  However, recent 127 
studies in mouse models have further implicated Gardnerella vaginalis as a cause of features 128 
related to BV. 25,26 These unknowns and the fact that BV is a common condition in the U.S. 129 
underscore the importance of identifying BV-associated risk factors to identify women at high 130 
risk for adverse gynecologic and obstetric outcomes and to design more effective treatments and 131 
prevention strategies.  132 
 133 
While a relationship between increased body mass index (BMI) and gut dysbiosis has been 134 
widely studied, 27–32 little is known about the relationship between BMI and BV prevalence. 135 
Most recently, it has been reported that the vaginal microbiota of overweight and obese Korean 136 
women exhibited a larger proportion of Lactobacillus iners and Prevotella compared to lean 137 
women.33,34 This is of interest since both of these taxa have been previously associated with 138 
BV.35,36 While these studies suggest there may be an increased prevalence of BV in 139 
overweight/obese women, participant BV status was not reported.33,34 One study conducted 140 
among U.S. women reported a positive correlation between high BMI and BV; however, after 141 
multivariable modeling, this study showed BMI was not independently associated with BV.37 142 
This study had several caveats including that less than one third of the women examined were 143 
black, and it did not examine the relationship between BMI and women with an “intermediate” 144 
microbiota (Nugent score 4-6). Moreover, all obese women were categorized into a single BMI 145 
group regardless of the subclass of obesity. Both NIH and WHO categorize obese individuals 146 
into three subclasses based on BMI: Class I (30-34.9 kg/m2), Class II (35-39.9 kg/m2) and Class 147 
III (≥40 kg/m2),38,39 and reports have shown an association between obesity class level and an 148 
increased prevalence of disease.40,41 Given the racial disparities among overweight and obese 149 
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women, and the higher prevalence of BV in black women, understanding the relationship 150 
between BV and BMI, and the role of race, is highly warranted.1,42–44 151 
 152 
To increase our understanding of the vaginal microbiota among overweight/obese women, and 153 
the extent to which this association may be influenced by race, we examined the correlation 154 
between BMI, Nugent score, and BV prevalence among women in the St. Louis region. 155 
Specifically, we examined whether BMI positively correlated with higher Nugent scores and 156 
increased BV prevalence. To test whether factors such as race influenced the proposed 157 
relationships, we performed multivariable modeling using information gathered from 5,918 158 
reproductive aged women, of whom 50.7% were black. 159 
 160 
Materials and Methods 161 
Study design 162 
We conducted a cross-sectional sub-study of participants from the Contraceptive CHOICE 163 
Project (CHOICE).45 CHOICE obtained written informed consent from all participants before 164 
enrollment in accordance with its approved IRB protocol from Washington University in St. 165 
Louis. CHOICE participants consented to the use of questionnaire data and stored vaginal 166 
samples by future sub-studies. The current sub-study obtained IRB approval (ID# 201108155) 167 
from Washington University in St. Louis and followed the principles outlined in the Declaration 168 
of Helsinki for human research. 169 
 170 
Over a 4-year period, CHOICE enrolled 9,256 women from the St. Louis region and provided 171 
FDA-approved reversible contraceptive methods at no-cost.45 Eligibility criteria included women 172 
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14 to 45 years of age, self-reported sexual activity in the past 6 months or plans to become 173 
sexually active with a male partner, and a desire to prevent pregnancy through the use of a 174 
reversible contraceptive method. Participants with a history of tubal ligation or hysterectomy 175 
were excluded from the study. The CHOICE cohort predominantly consisted of black and white 176 
participants, which is representative of the racial make-up of the St. Louis region. The current 177 
sub-study only included women with a complete baseline questionnaire survey, BMI 178 
measurement, and Nugent score (n= 5,918). The baseline questionnaire included age, self-179 
reported race and ethnicity, highest level of education obtained, monthly income, receipt of 180 
public assistance, difficulty paying for basic necessities, tobacco history, number of sexual 181 
partners, history of douching in last 30 and 180 days, history of STIs or positive for an STI at 182 
enrollment. Menstrual status was estimated as last menstrual period within 6 days of enrollment 183 
and a flag for recent hormonal contraceptive method use was created for those who reported 184 
contraceptive pills, patch, ring or injection, the levonorgestrel intrauterine system or subdermal 185 
implant. History of STI was defined as ever told by a healthcare provider that had one of the 186 
following sexually transmitted infections: chlamydia, gonorrhea, trichomoniasis, syphilis, human 187 
papillomavirus or genital warts, human immunodeficiency virus or herpes; current STI was 188 
defined as positive test for Chlamydia trachomatis, Neisseria gonorrhoeae or Trichomonas 189 
vaginalis at enrollment.  190 
 191 
Assessment of Bacterial Vaginosis 192 
At the time of CHOICE enrollment and prior to LARC method insertion, participants were 193 
instructed by a medical professional for self-collection of vaginal fluid from a mid-vaginal site 194 
(approximately 2 inches into the vagina) using a double-headed rayon swab (Starplex Scientific 195 
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Inc., Etobicoke, Ontario, Canada). Vaginal swabs were immediately rolled onto glass slides to 196 
create vaginal smears, which were Gram-stained and scored using the Nugent method.14 The 197 
Nugent method consisted of microscopic evaluation of bacterial morphotypes to score the overall 198 
character of the vaginal flora.14 Nugent scores range from 0 to 10 based on the prevalence of 199 
three bacterial morphotypes that roughly correspond to Lactobacillus, Gardnerella vaginalis or 200 
Bacteroides, and Mobiluncus. The number of long rod-shaped Gram-positive bacilli are scored 201 
0-4, where 0 indicates high numbers of Lactobacillus; small Gram-negative and Gram-variable 202 
rods and coccobacilli (Bacteroides and G. vaginalis) scored 0-4, with 4 denoting the highest 203 
observed number of these bacteria; and curved rods (e.g. Mobiluncus spp.) scored 0-2, where 2 204 
indicates the highest observed numbers. To ensure consistency in the amount of vaginal fluid on 205 
each slide and Gram-staining and Nugent scoring, all swabs were rolled by the same technician 206 
and all slides were stained and scored by the same technician. To assess the reliability of our 207 
scoring, a subset of smears we scored were also scored by the laboratory of Dr. Sharon Hillier 208 
(who established the Nugent score method14) at the Magee-Womens Research Institute, 209 
University of Pittsburgh and was reproducible between both research groups. Samples were 210 
categorized as BV-negative (score 0-3), BV-intermediate (score 4-6), or BV-positive (score 7-211 
10).  212 
 213 
 BMI determination 214 
Weight and height of participants were measured at the clinics by research personnel using a 215 
standardized protocol at the time of enrollment. Weight was recorded in pounds and height in 216 
feet and inches. Participants removed shoes and heavy outer clothing before being measured. 217 
This data was converted to BMI using the formula published by the Centers for Disease Control  218 
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and Prevention:46  (weight (lb)/[height(in)]2) x 703. Women were categorized by BMI based on 219 
NIH and WHO recommendations: underweight (<18.5 kg/m2), lean (18.5-24.9, overweight (25-220 
29.9 kg/m2), and Class I obese (30-34.9 kg/m2), Class II (35-39.9 kg/m2) obese and Class III 221 
(≥40 kg/m2) obese.38,39 222 
 223 
Statistical analysis 224 
Participant characteristics were described for all women and among strata of BMI categories. P-225 
values for these comparisons were estimated using chi-square tests (all categorical variables) or 226 
linear regression (age). We examined multiple metrics of BV in relation to BMI: Nugent score 227 
category (including intermediate), Nugent-defined bacterial vaginosis, and symptomatic BV 228 
(report of discharge, itching, odor or pain during urination47 during the 7 days prior to the clinic 229 
visit and sample collection).  230 
 231 
Crude and adjusted mean differences and 95% confidence intervals were estimated using linear 232 
regression stratified by BMI among all participants and by self-identified race group (black or 233 
white). Potential confounders (listed in Table 1) were evaluated for association with body mass 234 
index and Nugent score.  All variables that were significant at the alpha < 0.05 level were 235 
retained for inclusion in the fully adjusted model. Hispanic ethnicity and ever use of tobacco 236 
were not associated with Nugent score and were excluded. Variables that were significant in the 237 
fully adjusted model (public assistance, education, current smoker, douching in the last 30 days, 238 
sexually transmitted infection at baseline, and current hormonal contraception) were included in 239 
the final adjusted model. The All Participant models were also adjusted for race. Prevalence 240 
ratios of BV were estimated using Poisson regression with robust error variance. This approach 241 
provides an unbiased estimate of the prevalence ratio in the instance of a common binary 242 
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outcome. The p-value for the interaction term for BMI and race served as an indicator of effect 243 
modification. P-values for two-tailed tests less than alpha = 0.05 were considered statistically 244 
significant. All analyses were conducted in Stata 13.0 (StataCorp LP, College Station, TX). 245 
 246 
Results 247 
Participant characteristics 248 
Of the 9,256 CHOICE participants, 6,022 (65.1%) had a baseline questionnaire survey, BMI 249 
measurement, and Nugent score. The main reason for missingness (N=2,417, 26.1%) was 250 
absence of a vaginal smear for Nugent scoring, an element added to the protocol after enrollment 251 
began. Of the 6,022 eligible participants, 5,918 (98.3%) had complete data and were included in 252 
the current analysis. Participant data and vaginal specimens were obtained at the time of 253 
enrollment. Participants averaged 25.3 years old, and 50.7% self-identified as black (Table 1). 254 
Over half of participants (52.9%) reported a monthly income of $800 or less and 38.1% reported 255 
some form of public assistance at enrollment. One third of participants (33.9%) reported a high 256 
school diploma as the highest degree obtained. Most women reported multiple lifetime sexual 257 
partners (median=3); 27.5% of participants reported 2-4 partners, 29.2% reported 5-7, 14.2% 258 
reported 8-12, and 19.7% reported 13 or more lifetime sexual partners. Forty-six percent had a 259 
history of smoking, with 23.1% self-reporting as current smokers at the time of enrollment.  260 
 261 
In this cohort, 27.3% of women were BV-intermediate and 28.1% were BV-positive (Table 2). 262 
Of the women diagnosed as BV-positive, 17.2% reported symptoms associated with BV (i.e., 263 
abnormal discharge, foul odor, and vaginal itching47) at the time of enrollment. 264 
 265 
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BV prevalence by BMI category  266 
Of the 5,918 study participants, 2.9% were underweight (BMI <18.5 kg/m2), 39.1% were lean 267 
(BMI 18.5-24.9 kg/m2), 26% were overweight (BMI 25-29.9 kg/m2), and 32% were obese (BMI 268 
≥30 kg/m2) (Table 1). As shown in Table 2, 34.5% of obese, 30.4% of overweight, and 21.3% of 269 
lean women were BV-positive. Given that we observed no relationship between BMI and BV-270 
intermediate scores in this cohort, we examined the number of women below the threshold of BV 271 
(BV-negative and -intermediate) and found it to be highest among lean women (78.7%) and 272 
lowest among obese women (65.5%) (Table 2).  273 
 274 
We next examined whether a relationship existed between obesity class and BV prevalence. Due 275 
to the limited number of Class II and III obese individuals in this cohort, members of these two 276 
classes (BMI ≥35 kg/m2) were grouped together (n=958) and members of Class I (n=934) 277 
remained separate. Nugent scores were higher in overweight (0.33 [95% CI 0.14, 0.51]), Class I 278 
obese (0.51 [95% CI 0.29, 0.72]), and Class II/III obese groups (0.37 [95% CI 0.16, 0.59]) 279 
compared to lean women (Table 3). Consistent with this observation, the adjusted prevalence 280 
ratio of BV was 1.25 (95% CI 1.12, 1.39) for overweight, 1.31 (95% CI 1.16, 1.47) for Class I 281 
obese, and 1.25 (95% CI 1.11, 1.41) for Class II/III obese women compared to lean women 282 
(Table 4, 5th column). 283 
 284 
The role of race in the BMI-BV relationship 285 
To determine whether the relationship between BMI and BV was influenced by race, we 286 
performed a within race analysis of the mean difference in Nugent scores and the prevalence 287 
ratio of BV among black women (n=3,001) in each BMI category. Adjusted Nugent scores were 288 
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higher in overweight (0.30 [95% CI 0.01, 0.58)] and Class I obese (0.41 [95% CI 0.10, 0.73]) 289 
black women, compared to lean black women (Table 3). However, the adjusted Nugent scores of 290 
Class II/III obese black women were not significantly different compared to lean counterparts. 291 
Among white women (n=2,457), Nugent scores were higher for Class I (0.56 [95% CI 0.23, 292 
0.89]) and Class II/III (0.58 [95% CI 0.21, 0.95]) obese white women compared to lean white 293 
women. We observed no significant difference in Nugent scores for overweight white women 294 
compared to lean white women (Table 3).  295 
 296 
We next examined the adjusted prevalence ratio of BV for black women across all BMI 297 
categories. We observed that only Class I obese black women had an increased occurrence of BV 298 
(1.14 [95% CI 1.00, 1.31]) compared to lean black women, while the prevalence of BV for 299 
overweight and Class II/III obese black women was not statistically different than lean black 300 
women (Table 4). Among white women, the adjusted prevalence ratio of BV was greater in 301 
overweight (1.44 [95% CI 1.16, 1.79), Class I (1.73 [95% CI 1.35, 2.22]), and Class II/III (1.63 302 
[95% CI 1.23, 2.15]) obese white women compared to lean white women (Table 4). We next 303 
examined the effect modification of race on the BMI-BV relationship. The statistical interaction 304 
of increasing BMI and race in relation to BV prevalence was significant for overweight (p 305 
=0.024) and obese (class I, p = 0.001 and class II/III, p = 0.002) women (Table 4). No interaction 306 
of race was observed in the association of BMI and Nugent score (Table 3). 307 
 308 
Comment 309 
We report that Nugent scores were higher in overweight (4.53) and obese (class I - 4.87, and 310 
class II/III - 4.93) women compared to lean (3.90) women. Overweight and obese women also 311 
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had a higher frequency of BV (overweight - 25%, and obese class I - 31% and class II/III - 25%; 312 
adjusted). Because black race is a risk factor for both BV and obesity in women, 1,44–46 we 313 
examined the relationship between BMI and BV by race. Among white women,  Nugent scores 314 
were higher in obese (class I - 3.99 and class II/III - 4.08) women than in lean (3.21) women. 315 
White overweight (19.9%) and obese (class I - 24.7% and class II/III - 24.2%) women had a 316 
higher prevalence of BV compared to lean (12.5%) white women. However, among black 317 
women, this phenomenon was not present, suggesting that BV occurrence in black women is 318 
independent of their BMI. We observed a significant interaction of race and increasing BMI in 319 
relation to BV prevalence for overweight (p = 0.024) and obese (class I p = 0.001 and class II/II 320 
p = 0.002) women, suggesting race is an effect modifier of the association of increasing BMI and 321 
BV prevalence. While the interaction of race on the BMI-BV relationship has not been 322 
previously reported, studies have shown obese white women exhibit a higher avoidance of 323 
female preventative health care services (e.g., Papanicolau test and breast cancer screening), a 324 
phenomenon not observed in obese black women.48,49 Multiple factors likely contribute to the 325 
significant interaction between race, BMI, and BV in our study; the previously observed higher 326 
level of delay and avoidance toward preventative genital health services among obese white 327 
women may be one factor.50 328 
 329 
 Few studies have explored the relationship between BMI and BV prevalence, and a consensus 330 
on whether BMI is a risk factor for BV has not been reached. In one study of 2,906 U.S. women, 331 
of which 26.2% were black, 36% of obese women were BV positive; however, after adjusting for 332 
confounders, there was no relationship between BMI and BV.37 This apparent discrepancy may 333 
be due to our larger sample size (n=5,918), a larger representation of black women (50.7%), and 334 
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potential differences in the differential control of confounders and levels of residual confounding 335 
between our study and Koumans et al. A recent longitudinal study reported obesity was 336 
associated with nearly a 20% decrease of BV risk in a cohort of 1,946 Kenyan female sex-337 
workers.51  The longitudinal Kenyan study measured relative risk of BV in obese populations 338 
while our cross sectional study measured prevalence (e.g., one infers a causal relationship while 339 
the other offers association). Differences in the characteristics of the Kenyan cohort and our 340 
cohort may also account for the discrepancy between the two studies, for example, our larger 341 
sample size (n=5,918 total and n=3,001 black women versus their n=1,946). Additionally, their 342 
cohort consisted of only African women, while our analysis included women of white (41.5%), 343 
black (50.7%), and other (7.8%) races. This difference may be important since African and black 344 
women exhibit a higher incidence of vaginal microbiota disruption compared to white 345 
women,52,53 thus results of one race may vary from results of other races. Expanding on this 346 
point, our within race analyses (Tables 3-4) show that in white women, increasing BMI is 347 
associated with a higher incidence of a disrupted vaginal microbiota and increased prevalence of 348 
BV; however, for black women, the same comparison did not reach statistical significance. Other  349 
differences include a high HIV prevalence (41.8%) and the women studied were sex workers; the 350 
obese women in the study also appeared to be more likely to have high CD4 counts compared to 351 
normal women. Whether these characteristics influenced BV risk in the Kenyan population was 352 
not explored. Additional studies are needed to fully understand the relationship between BMI 353 
and BV prevalence in different geographic populations. 354 
 355 
Given the complex nature of obesity, mechanisms contributing to the increased occurrence of 356 
BV in obese women are expected to be multifactorial. While reports have shown a positive 357 
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correlation between overweight/obese women and the presence of BV-associated microbiota,33,34 358 
the mechanisms at play remain unknown. Obesity may generate a favorable environment for BV 359 
through disturbances in host hormonal, metabolic, and/or immune functions. Diet may also 360 
influence the BMI-BV relationship, since certain dietary habits have been associated with 361 
BV.54,55 A potential role for the gut microbiota in BV is also plausible, since the gut microbiota 362 
has been suggested to influence the composition of the vaginal microbiota by serving as an 363 
extravaginal reservoir of bacteria.56 In addition, given the higher prevalence of menstrual 364 
irregularity in obese women, the presence of blood may alter vaginal flora.  The role of douching 365 
in the BMI-BV relationship should also be considered, since douching is associated with BV and 366 
was found in one study to be practiced more often among obese women.37 The mechanisms that 367 
contribute to the BMI-BV relationship may best be explored via established animal models of 368 
obesity and BV,25 which would allow for a causal analysis of the role of specific factors such as 369 
obesity-associated hormonal and metabolic dysfunctions, dietary habits, the gut microbiota, and 370 
the synergistic effects these factors may exhibit.  371 
 372 
This study had both strengths and limitations. Our 5,918 cohort represented a diverse group of 373 
women socioeconomically and racially. BMI and Nugent score were determined for each 374 
participant by trained clinical staff using universally approved and established guidelines.14,46 375 
Reproducibility of our Nugent scoring was verified by Dr. Sharon Hillier’s laboratory (developer 376 
of the Nugent scoring method 14), for a sample of specimens. In this cohort, 28.1% of women 377 
were BV-positive, a figure similar to estimates from a representative sample of U.S. reproductive 378 
aged women (29%), 57 and at the time of enrollment, 17.2% of BV-positive women reported 379 
symptoms associated with BV, a percentage consistent with another report (15.7%), 37 thus 380 
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underscoring the commonly asymptomatic nature of BV from the patient perspective. 381 
Limitations in our study included small numbers of underweight and Class II and III obese 382 
women, a cross-sectional design, and a lack of information on recent antibiotic use. Also, our 383 
study focuses on two races, black and white, and does not focus on the relationship between BMI 384 
and BV in other racial populations, since the sample size of other races in our cohort was small. 385 
 386 
Obesity and BV pose serious threats to women’s health and black race is a risk factor for both of 387 
these conditions. Our study demonstrates overweight and obesity are associated with higher 388 
Nugent scores and increased prevalence of BV, and the relationship between BMI and BV 389 
prevalence varies between black and white women. Our observations indicate additional efforts 390 
to understand the relationship between obesity and BV and the influence of BMI on the vaginal 391 
microbiome in racially diverse cohorts are highly warranted. 392 
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Table 1. Demographics of CHOICE Participants by BMI Category, N=5,918 588 
 All Participants by BMI Category (kg/m2)  
 Participants Underweight 
< 18.5 
Lean 
18.5-24.9 
Overweight  
25-29.9 
Class I Obese  
30-34.9 
Class II/III Obese  
       ≥ 35 
 N=5918 N=174 N=2,312 N=1,540 N=934 N=958 p-value* 
Age, mean(SD) 25.3 (5.9) 23.2 (4.7) 24.1 (5.4) 25.6 (6.0) 26.1 (6.2) 26.9 (6.1) <0.001 
Race        
   Black 3001 (50.7) 72 (41.4) 870 (37.6) 809 (52.5) 570 (61.0) 680 (71.0) <0.001 
   White 2457 (41.5) 84 (48.3) 1250 (54.1) 604 (39.2) 296 (31.7) 223 (23.3)  
   Other 460 (7.8) 18 (10.3) 192 (8.3) 127 (8.3) 68 (7.3) 55 (5.7)  
Hispanic 300 (5.1) 9 (5.2) 105 (4.5) 99 (6.4) 53 (5.7) 34 (3.6) 0.014 
Monthly income        
   None 1226 (20.8) 35 (20.1) 524 (22.7) 304 (19.8) 187 (20.1) 176 (18.4) <0.001 
   $1-800 1903 (32.3) 75 (43.1) 780 (33.9) 494 (32.1) 258 (27.7) 296 (31.0)  
   $801-1600 1666 (28.2) 45 (25.9) 587 (25.5) 436 (28.4) 295 (31.7) 303 (31.7)  
   $1601+ 1106 (18.7) 19 (10.9) 413 (17.9) 304 (19.8) 190 (20.4) 180 (18.9)  
Receiving public assistance 2250 (38.1) 48 (27.8) 639 (27.7) 625 (40.6) 445 (47.7) 493 (51.5) <0.001 
Trouble paying for basic 
necessities 
2393 (40.5) 62 (35.6) 828 (35.9) 625 (40.6) 433 (46.4) 445 (46.5) <0.001 
Education        
   ≤ High school 2007 (33.9) 71 (40.8) 734 (31.8) 535 (34.8) 345 (37.0) 322 (33.6) <0.001 
   Some college 2512 (42.4) 67 (38.5) 895 (38.7) 670 (43.5) 408 (43.8) 472 (49.3)  
   College graduate 1396 (23.6) 36 (20.7) 683 (29.5) 334 (21.7) 179 (19.2) 164 (17.1)  
Ever smoking 2765 (46.7) 79 (45.4) 1123 (48.6) 731 (47.5) 514 (55.0) 546 (57.0) 0.037 
Current smoking 1367 (23.1) 48 (27.6) 550 (23.8) 374 (24.3) 199 (21.3) 196 (20.5) 0.044 
Sexual partners last 30 days        
   None 1125 (19.2) 21 (12.4) 390 (17.1) 316 (20.7) 191 (20.7) 207 (21.8) 0.004 
   One 4356 (74.5) 136 (80.0) 1750 (76.8) 1124 (73.6) 673 (72.8) 673 (70.9)  
   2 or more 370 (6.3) 13 (7.7) 139 (6.1) 88 (5.8) 61 (6.6) 69 (7.3)  
Lifetime sexual partners        
   None 39 (0.7) 0  12 (0.5) 14 (0.9) 4 (0.4) 9 (1.0) <0.001 
   One 516 (8.7) 14 (8.1) 253 (10.9) 128 (8.3) 72 (7.7) 49 (5.1)  
   2-4 1630 (27.5) 56 (32.2) 680 (29.4) 433 (28.1) 231 (24.7) 230 (24.0)  
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   5-7 1727 (29.2) 56 (32.2) 646 (27.9) 428 (27.8) 303 (32.4) 294 (30.7)  
   8-12 839 (14.2) 15 (8.6) 308 (13.3) 225 (14.6) 136 (14.6) 155 (16.2)  
   13 or more 1167 (19.7) 33 (19.0) 413 (17.9) 312 (20.3) 188 (20.1) 221 (23.1)  
Douching in the past 180 days 1340 (22.7) 32 (18.4) 407 (17.6) 354 (23.0) 248 (26.6) 299 (31.2) <0.001 
Douching in the past 30 days 590 (10.0) 19 (10.9) 168 (7.3) 162 (10.6) 99 (10.6) 142 (14.9) <0.001 
Past sexually transmitted 
infection 
2461 (41.6) 63 (36.2) 801 (34.7) 660 (42.9) 441 (47.2) 496 (51.8) <0.001 
Sexually transmitted infection 
at baseline 
518 (8.8) 17 (9.8) 170 (7.4) 132 (8.6) 85 (9.1) 114 (11.9)   0.001 
Current menstruation flag 856 (14.5) 19 (10.9) 342 (14.8) 216 (14.0) 129 (13.8) 150 (15.7)  0.458 
Current hormonal 
contraceptive method prior to 
enrollment 
1520 (25.7) 38 (21.8) 636 (27.5) 412 (26.8) 199 (21.3) 235 (24.5)  0.003 
        
Except for age, all demographics are reported as N (%). SD – standard deviation; BMI – body mass index 589 
*p-values were determined using chi-square test (all categorical variables) or linear regression (age). For categorical variables, p-590 
values represent the distribution of a given categorical variable for All Participants and within a specific BMI category, as shown. 591 
 592 
  593 
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Table 2. Nugent Score and Prevalence of BV by BMI Category 594 
 All Participants by BMI Category (kg/m2)  
 Participants Underweight 
< 18.5 
Lean 
18.5-24.9 
Overweight 
25-29.9 
Class I Obese 
30-34.9 
    Class II/III Obese 
      ≥ 35 
Nugent score - BV status N=5918 N=174 N=2,312 N=1,540 N=934 N=958 p-value* 
Nugent score        
   0-3 2639 (44.6) 78 (44.8) 1170 (50.6) 657 (42.7) 370 (39.6) 364 (38.0) <0.001 
   4-6 1618 (27.3) 48 (27.6) 649 (28.1) 415 (27.0) 247 (26.5) 259 (27.0)  
   7-10 1661 (28.1) 48 (27.6) 493 (21.3) 468 (30.4) 317 (33.9) 335 (35.0)  
Bacterial vaginosis        
   No 4257 (71.9) 126 (72.4) 1819 (78.7) 1072 (69.6) 617 (66.1) 623 (65.0) <0.001 
   Yes 1661 (28.1) 48 (27.6) 493 (21.3) 468 (30.4) 317 (33.9) 335 (35.0)  
      Symptomatic BV        
         No 1376 (82.8) 41 (85.4) 406 (82.4) 379 (81.0) 261 (82.3) 289 (86.3) 0.371 
         Yes 285 (17.2) 7 (14.6) 87 (17.7) 89 (19.0) 56 (17.7) 46 (13.7)  
All variables are reported as N (%). BV – bacterial vaginosis; BMI – body mass index 595 
*p-values were determined using chi-square test for categorical variables. p-values represent the distribution of a given categorical 596 
variable for All Participants and within a specific BMI category, as shown. 597 
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Table 3. Mean Difference in Nugent Score by BMI Category Overall and Within Each Race 598 
 
BMI 
Category 
(kg/m2) 
 
Mean 
Nugent 
Score (SD) 
Mean Difference in Nugent Score 
(95% Confidence Interval) 
        Crude             Fully Adjusted*   Final Adjusted** 
Black v. 
White 
Interaction 
p-value 
All 
Women† 
     
< 18.5 4.27 (3.01) 0.30 (-0.14, 0.73) 0.15 (-0.29, 0.58) 0.19 (-0.24, 0.62) 0.557 
18.5-24.9 3.90 (2.85) Referent Referent Referent Referent 
25-29.9 4.53 (2.94) 0.40 (0.22, 0.59) 0.29 (0.11, 0.48) 0.33 (0.14, 0.51) 0.891 
30-34.9 4.87 (2.99) 0.61 (0.39, 0.83) 0.44 (0.23, 0.66) 0.51 (0.29, 0.72) 0.401 
≥ 35 4.93 (2.96) 0.53 (0.31, 0.75) 0.28 (0.07, 0.50) 0.37 (0.16, 0.59) 0.064 
 
     
Black 
Women 
     
< 18.5 5.08 (3.02) 0.10 (-0.62, 0.83) 0.00 (-0.72, 0.72) 0.00 (-0.72, 0.71)  
18.5-24.9 4.98 (3.01) Referent Referent Referent  
25-29.9 5.24 (3.01) 0.26 (-0.03, 0.55) 0.23 (-0.06, 0.52) 0.30 (0.01, 0.58)  
30-34.9 5.37 (3.06) 0.39 (0.07, 0.71) 0.34 (0.02, 0.66) 0.41 (0.10, 0.73)  
≥ 35 5.19 (3.00) 0.21 (-0.09, 0.51) 0.07 (-0.23, 0.38) 0.18 (-0.12, 0.48)  
 
     
White 
Women 
     
< 18.5 3.63 (2.79) 0.43 (-0.15, 1.01) 0.23 (-0.34, 0.81) 0.30 (-0.28, 0.87)  
18.5-24.9 3.21 (2.51) Referent Referent Referent  
25-29.9 3.62 (2.70) 0.42 (0.16, 0.67) 0.24 (-0.02, 0.49) 0.24 (-0.01, 0.49)  
30-34.9 3.99 (2.78) 0.78 (0.45, 1.11) 0.51 (0.18, 0.84) 0.56 (0.23, 0.89)  
≥ 35 4.08 (2.71) 0.88 (0.50, 1.25) 0.51 (0.13, 0.88) 0.58 (0.21, 0.95)  
       
BMI – body mass index; SD – standard deviation; statistically significant values are in bold. 599 
* Fully adjusted model included income, public assistance, trouble paying for basics, education, 600 
number of sex partners in the last 30 days, lifetime number of sex partners, current tobacco use, 601 
douching in last 30 days, douching in last 180 days, history of sexually transmitted infection, 602 
current sexually transmitted infection. 603 
** Final model adjusted for public assistance, education, current smoker, douching in the last 30 604 
days and sexually transmitted infection at baseline.  605 
† The All Women model was also adjusted for race. 606 
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Table 4. Prevalence Ratio of BV by BMI Category Overall and Within Each Race 617 
 
BMI 
Category 
(kg/m2) 
 
BV 
Prevalence 
Prevalence Ratio 
(95% Confidence Interval) 
       Crude             Fully Adjusted*    Final Adjusted** 
Black v. 
White 
Interaction 
p-value 
All 
Women† 
     
< 18.5 27.6% 1.25 (0.98, 1.60) 1.18 (0.92, 1.51) 1.20 (0.94, 1.54) 0.314 
18.5-24.9 21.3% Referent Referent Referent Referent 
25-29.9 30.4% 1.28 (1.15, 1.43) 1.23 (1.10, 1.36) 1.25 (1.12, 1.39) 0.024 
30-34.9 33.9% 1.36 (1.20, 1.53) 1.26 (1.12, 1.42) 1.31 (1.16, 1.47) 0.001 
≥ 35 35.0% 1.31 (1.16, 1.48) 1.20 (1.07, 1.35) 1.25 (1.11, 1.41) 0.002 
 
     
Black 
Women 
     
< 18.5 38.9% 1.11 (0.82, 1.50) 1.08 (0.80, 1.46) 1.07 (0.79, 1.45)  
18.5-24.9 35.2% Referent Referent Referent  
25-29.9 39.1% 1.11 (0.98, 1.26) 1.09 (0.97, 1.24) 1.12 (0.99, 1.27)  
30-34.9 39.8% 1.13 (0.99, 1.30) 1.11 (0.97, 1.27) 1.14 (1.00, 1.31)  
≥ 35 37.8% 1.07 (0.94, 1.23) 1.03 (0.90, 1.17) 1.07 (0.98, 1.18)  
 
     
White 
Women 
     
< 18.5 19.1% 1.53 (0.96, 2.43) 1.37 (0.86, 2.18) 1.44 (0.92, 2.25)  
18.5-24.9 12.5% Referent Referent Referent  
25-29.9 19.9% 1.59 (1.28, 1.98) 1.42 (1.14, 1.76) 1.44 (1.16, 1.79)  
30-34.9 24.7% 1.98 (1.54, 2.53) 1.69 (1.31, 2.17) 1.73 (1.35, 2.22)  
≥ 35 24.2% 1.94 (1.47, 2.55) 1.56 (1.18, 2.07) 1.63 (1.23, 2.15)  
      
BV – bacterial vaginosis; BMI – body mass index; statistically significant values are in bold. 618 
* Fully adjusted model included income, public assistance, trouble paying for basics, education, 619 
number of sex partners in the last 30 days, lifetime number of sex partners, current tobacco use, 620 
douching in last 30 days, douching in last 180 days, history of sexually transmitted infection, 621 
current sexually transmitted infection. 622 
** Final model adjusted for public assistance, education, current smoker, douching in the last 30 623 
days and sexually transmitted infection at baseline.  624 
† The All Women models also adjusted for race. 625 
